Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Vered Caplan | F | 55 | 12 years | |
David Sidransky | M | 64 | 11 years | |
Mario Philips | M | 54 | 4 years | |
Yaron Adler | M | 54 | 12 years | |
Guy Yachin | M | 55 | 12 years | |
Sarah Ferber | M | 70 | 16 years | |
Ashish Nanda | M | 59 | 7 years | |
Victor Miller | M | 54 | - | |
Gerhard Bauer | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Neil Reithinger | M | 54 | 9 years | |
Elliot Maltz | M | 39 | - | |
Manfred Rüdiger | M | 59 |
Cardion GmbH
Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | 5 years |
Claudia Zylberberg | M | - | - | |
Osher Rheinisch | F | 52 | 1 years | |
Thomas Schulze | M | 61 |
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | 7 years |
Thomas Mathers | M | 56 |
Cardion GmbH
Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | 1 years |
Thomas H. Moll | M | 58 |
Cardion GmbH
Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | 5 years |
Efrat Assa-Kunik | M | 49 | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 14 | 77.78% |
Germany | 4 | 22.22% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Heiko von der Leyen
- Personal Network